Anavex Life Sciences (AVXL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AVXL Anavex Life Sciences

Watchlist

8.630
+0.160+1.89%

Close Dec 20 16:00 ET

8.501
-0.129-1.50%

Post 20:01 ET

731.79MMarket Cap-16.92P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Anavex Life Sciences, Limoneira Set to Report Earnings Monday
InvestingDec 20 14:02 ET
Earnings Preview: AVXL to Report Financial Results Pre-market on December 23
Moomoo NewsDec 17 20:00 ET
Anavex Life Sciences Corp. to Announce Fiscal Year 2024 Financial Results on December 23, 2024
Quiver QuantitativeDec 16 07:41 ET
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference
GlobeNewswireDec 9 07:30 ET
Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More
Seeking AlphaDec 8 08:01 ET
Anavex Life Sciences Down Over 13%, On Track for Largest Percent Decrease Since January -- Data Talk
Dow JonesDec 5 15:12 ET

Comments

Daily Investors

Dec 20 08:01

Miss

$Anavex Life Sciences (AVXL.US)$ a Good Company, and def undervalued. They have done so much in the past 6 months. However where they are at, there not making money, just research

Rhiox

Dec 16 08:43

$Anavex Life Sciences (AVXL.US)$ crossing over mid Bollinger band on day chart , possible to see 9. + soon

Rhiox

Dec 13 15:48

$Anavex Life Sciences (AVXL.US)$
$Sunshine Biopharma (SBFM.US)$
$Rumble (RUM.US)$
Got a few superbouncy balls this evening.
making me dizzy 🤣

Rhiox

Dec 12 08:26

$Anavex Life Sciences (AVXL.US)$ 👀

Jaguar8

Dec 9 06:55

NEWS

$Anavex Life Sciences (AVXL.US)$
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...

Heat List

Overall

No Data